
|Articles|August 20, 2014
- Immunotherapy (Issue 3)
- Volume 3
- Issue 1
Combining Immunotherapies With Targeted Therapies and Other Immunotherapies
Author(s)Gregory A. Daniels, MD, PhD
Gregory A. Daniels, MD, PhD, discusses opportunities to combine immunotherapies with both targeted therapies and other immunotherapies.
Advertisement
Gregory A. Daniels, MD, PhD, associate clinical professor of medicine, Division of Hematology-Oncology, University of California, San Diego, discusses opportunities to combine immunotherapies with both targeted therapies and other immunotherapies. Daniels references the results of the 2007-2012 PROCLAIM National Registry, which was presented at the 2014 ASCO Annual Meeting.
Read about combining immunotherapies > >
Articles in this issue
over 11 years ago
A Brief History of Immunotherapyover 11 years ago
Better Biomarker Testing Needed in Immuno-Oncologyover 11 years ago
Autoimmunity and Limitations of Cancer Vaccinesover 11 years ago
The Management of Side Effects Associated With Immunotherapiesover 11 years ago
The Next Wave in Immunotherapy: Combinationsover 11 years ago
Future Immune Checkpoint StrategiesAdvertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
2
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5



















